While hexavalent vaccines may have higher upfront costs, they can help reduce adverse events, logistical challenges, and overall societal burdens, offering potential economic and practical benefits for immunization programs, as demonstrated by studies from countries including Peru (wP pentavalent compared to aP hexavalent), Argentina (wP pentavalent compared to aP hexavalent), Colombia (aP compared to wP hexavalent vaccines), and South Korea (DTaP-IPV-Hib-HepB compared to DTaP-IPV/Hib). Go to footnote 1, Go to footnote 2, Go to footnote 3, Go to footnote 4, Go to footnote 5, Go to footnote 6, Go to footnote 7
- Go back to footnote reference 1
Seinfeld, J., Rosales, M.L., Sobrevilla, A. & López Yescas, J.G. (2022). Economic assessment of incorporating the hexavalent vaccine as part of the National Immunization Program of Peru. BMC Health Services Research, 22(1), 651. doi:10.1186/s12913-022-08006-1.
- Go back to footnote reference 2
Olivera, I., Pérez, C.G., Lazarov, L., Lopez, E., Oddo, C. & Dibarboure, H. (2023). Cost minimization analysis of a hexavalent vaccine in Argentina. BMC Health Services Research, 23(1), 1067. doi:10.1186/s12913-023-10038-0.
- Go back to footnote reference 3
Romero, M., Góngora, D.-S., Caicedo, M.-L., Benchabane, D. & Lopez, J.-G. (2021). Cost-Minimization and Budget Impact Analysis of a Hexavalent Vaccine (Hexaxim®) in the Colombian Expanded Program on Immunization. Value in Health Regional Issues, 26, 150–159. doi:10.1016/j.vhri.2021.06.001.
- Go back to footnote reference 4
Min, S., Kwon, S.H., Lee, Y.W., Lee, J.M., Bae, E.J. & Lee, E.K. (2023). Estimating the Total Societal Cost of a Hexavalent Vaccine versus a Pentavalent Vaccine with Hepatitis B in South Korea. Vaccines (Basel), 11(5), 984. doi:10.3390/vaccines11050984.
- Go back to footnote reference 5
Olivera, M., Soto, J., Llamas, L.M., Reyes, N., Cid, M., et al. (2020) ‘Valuing the cost of improving Chilean primary vaccination: a cost minimization analysis of a hexavalent vaccine’, BMC Health Services Research, 20, p. 295. https://doi.org/10.1186/s12913-020-05115-7
- Go back to footnote reference 6
Aljunid, S.M., Ismail, A., Nor, N.M., Zafar, A., Suleiman, A., et al. (2022) ‘Economic impact of switching from partially combined vaccine “Pentaxim® and hepatitis B” to fully combined vaccine “Hexaxim®” in the Malaysian National Immunization Program’, BMC Health Services Research, 22, p. 34. https://doi.org/10.1186/s12913-021-07428-7
- Go back to footnote reference 7
Mogale, M., Burnett, R.J., Olivier, D., Mphahlele, J. (2014) ‘Economic assessment of implementing Hexaxim® vaccine within the South African Expanded Programme on Immunisation (EPI-SA)’, International Journal of Infectious Diseases, 21(Suppl.), pp. 1–460 (Abstract, 16th ICID).
